Merck has shared these additional analyses with the FDA and they will be presented to the FDA’s Antimicrobial Drugs Advisory Committee on Nov. 30th
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
The acquisition complements and strengthens Merck’s cardiovascular pipeline
If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
The medicine is now approved for eight indications across five different types of cancer in China.
The two-year donation supports the development of clinical tests for Covid-19 severity assessment and the focus on the development of simple immunoassays using single molecule counting technology
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
As of 2025, the new Translational Science Center will offer room for more than 500 scientists, who will conduct research in a wide variety of fields ranging from the identification of disease biomarkers to the development of targeted therapies
Subscribe To Our Newsletter & Stay Updated
